Page 119 - Screening for Cervical Cancer: Systematic Evidence Review
P. 119
Appendix C. Evidence Tables
Evidence Table 2. New Methods for Preparing or Evaluating Cervical Cytology (cont'd)
Patients & Methods Outcomes Measured Study Results & Limitations* Quality Considerations
AutoPap
3487 smears screened Blind interpretation AutoPap 20% review rate Quality Score=6
manually as negative Yield: Ref. Std: 0
No. of FN/No. (ASCUS+) = 57/3487 (1.6%) Blind: 2
rescreened (LSIL+) = 10/3487 (0.29%) Verification: 1
No. of FN with FN (AutoPap)/FN total Consecutive: 1
AutoPap/total FN (ASCUS+) = 57/86 (66.3%) Spectrum: 1
FN (AutoPap)/total (LSIL+) = Publication: 1 Industry: 0
GS: cytology 10/13 (76.9%)
(independent panel)
applied to discrepant
cases
Current archive No. of FN detected by AutoPap 10% review rate: Quality Score=4
sensitivity: 2339 Pap AutoPap/total FN Est. Se (ASCUS+) = 67/203 Ref. Std: 0
smears including (estimate of (33%) Blind: 2
positives and negative sensitivity) Est. Se (LSIL+) = 18/32 (56%) Verification: 0
controls; Consecutive: 0
Historic sensitivity study AutoPap 20% review rate: Spectrum: 1
3028 Pap smears Est. Se (ASCUS+) = 103/203 Publication: 1
comprising positiveand (51%) Industry: 0
negative controls Est. Se (LSIL+) = 21/32 (66%)
No data on specificity of
AutoPap rescreen
683 Pap smears Sensitivity and Se (ASCUS+) = 330/357 Quality Score=6
(264 normal) workload reduction (92.4%) Ref. Std: 0
Se (LSIL+) = 195/199 (98%) Blind: 2
GS: cytology Verification: 2
(independent panel) Feasibility study of location- Consecutive: 0
guided screening. Spectrum: 1
Publication: 1
No results for slides initially Industry: 0
read as normal.
1840 Pap smears No. of FN detected by AutoPap: Quality Score=6
initially read as normal AutoPap/total FN Est. Se: Ref. Std: 0
(estimated sensitivity) 30% review rate: 4/7 (52%) Blind: 2
20% review rate 3/7 (43%) Verification: 1
GS: cytology Consecutive: 1
(independent panel 10% manual review: Spectrum: 1
review of discrepant Est. Se 0/7 = 0% Publication: 1
cases) Industry: 0
C-25